This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.10% per year. These returns cover a period from January 1, 1988 through October 7, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Cardinal Health's (CAH) Arm Receives FDA Nod for LYMPHOSEEK
by Zacks Equity Research
Cardinal Health's (CAH) Nuclear & Precision Health Solutions receive FDA approval for LYMPHOSEEK injection.
BD's (BDX) Milestone Pandemic Orders to Support Vaccinations
by Zacks Equity Research
BD (BDX) receives 2 billion pandemic orders for needles and syringes to support global COVID-19 vaccination efforts.
Here's Why You Should Retain AmerisourceBergen (ABC) Now
by Zacks Equity Research
AmerisourceBergen (ABC) continues to gain traction from robust pharmaceutical segment.
AngioDynamics (ANGO) Receives FDA Nod for AlphaVac System
by Zacks Equity Research
AngioDynamics (ANGO) gets 510(k) clearance from the FDA for the AlphaVac System for the non-surgical removal of thrombi or emboli from the vasculature.
DENTSPLY SIRONA (XRAY) Boosts Clear Aligner Foothold With Buyout
by Zacks Equity Research
DENTSPLY SIRONA (XRAY) to fortifies its presence further in the clear aligner market with the acquisition of Propel Orthodontics.
Encompass Health (EHC) Buys Frontier, Boosts Home Health Services
by Zacks Equity Research
Encompass Health (EHC) completes the purchase of Frontier, which reflects its efforts to offer enhanced care across several states.
Why Is Encompass Health (EHC) Up 0.3% Since Last Earnings Report?
by Zacks Equity Research
Encompass Health (EHC) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Encompass Health (EHC) Gains on Strong Revenues & Cash Flows
by Zacks Equity Research
Encompass Health (EHC) set to benefit on the back of consistent top-line growth, robust 2021 business outlook and strong liquidity stand.
Canopy Growth (CGC) to Report Q4 Earnings: What's in Store?
by Zacks Equity Research
Continued robust product demand is expected to have significantly contributed to Canopy Growth's (CGC) top line in the fiscal fourth quarter.
EHC or CHE: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
EHC vs. CHE: Which Stock Is the Better Value Option?
What's in Store for Intersect ENT's (XENT) Q1 Earnings?
by Zacks Equity Research
PROPEL and SINUVA are expected to have contributed to Intersect ENT's (XENT) first-quarter revenues.
Zacks.com featured highlights include: Encompass Health, Facebook, MKS Instruments, Blackstone Group and Interpublic Group of Companies
by Zacks Equity Research
Zacks.com featured highlights include: Encompass Health, Facebook, MKS Instruments, Blackstone Group and Interpublic Group of Companies
Robust Sales Growth Make These 5 Stocks Worth Betting on Now
by Swayta Shah
Strong sales growth is one of the most important characteristics of potential winners in the stock market. Let's check out Encompass Health (EHC), Facebook (FB), MKS Instruments (MKSI), Blackstone (BX) and Interpublic Group (IPG) that may record solid sales growth.
7 Great Value Picks Based on Discounted PEG
by Urmimala Biswas
Here are seven out of the 50 stocks that qualify the screening.
EHC or CHE: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
EHC vs. CHE: Which Stock Is the Better Value Option?
Encompass Health (EHC) Q1 Earnings Beat, Hikes '21 View
by Zacks Equity Research
Encompass Health's (EHC) first-quarter results reflect improved Inpatient Rehabilitation segment revenues, partly offset by lower volumes in both its segments and higher costs.
Encompass Health (EHC) Tops Q1 Earnings and Revenue Estimates
by Zacks Equity Research
Encompass Health (EHC) delivered earnings and revenue surprises of 31.25% and 0.15%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?
Encompass Health (EHC) Takes Nationwide Hospital Count to 139
by Zacks Equity Research
Encompass Health (EHC) opens an inpatient rehabilitation hospital in Florida, which highlights its efforts to offer enhanced rehabilitative care in the state.
Encompass Health (EHC) Opens Hospital, Boosts Texas Presence
by Zacks Equity Research
Encompass Health (EHC) opens an inpatient rehabilitation hospital in Texas, which reinforces the company's efforts to broaden presence in the state.
Encompass Health (EHC) Set to Boost South Carolina Footprint
by Zacks Equity Research
Encompass Health (EHC) introduced plans to construct a hospital in South Carolina for offering enhanced rehabilitative care across the state.
Encompass Health (EHC) Continues to Expand Presence in Texas
by Zacks Equity Research
Encompass Health (EHC) plans to construct a hospital in Texas for offering improved rehabilitative services, which highlights its efforts to bolster presence in the state.
Encompass Health (EHC) Ties Up for Better Homehealth Care
by Zacks Equity Research
Encompass Health (EHC) forms partnership with Right at Home for value-based care models, which in turn, are expected to improve health outcomes.
Encompass Health (EHC) Unveils Plans to Expand in Maryland
by Zacks Equity Research
Encompass Health's (EHC) plans to construct a hospital is indicative of the company's efforts to offer improved healthcare services in southern Maryland.
Encompass Health (EHC) Q4 Earnings Beat Estimates, Rise Y/Y
by Zacks Equity Research
Encompass Health's (EHC) fourth-quarter results gain from improved revenues and lower costs, partly offset by lower volumes in both its segments.
Encompass Health (EHC) Beats Q4 Earnings and Revenue Estimates
by Zacks Equity Research
Encompass Health (EHC) delivered earnings and revenue surprises of 8.14% and 0.59%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?